DARA: DARA Biosciences, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 2:30 PM Dara Biosciences (DARA -3%) slips after its Q1 EPS missed estimates yesterday. Bottom line results were negatively impacted by costs incurred in the establishment of a sales and marketing, distribution and regulatory infrastructure to support the promotion of its oncology and oncology supportive care products. Comment! [Healthcare, Earnings, On the Move]
Wednesday, May 15, 4:59 PM Dara BioSciences (DARA): Q1 EPS of -$0.11 misses by $0.04. Revenue of $21.2K. Shares +2.7% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Wednesday, April 3, 8:56 AM Dara BioSciences (DARA +4.1%) signs an agreement with pharmacy benefit manager Prime Therapeutics for the latter to distribute Dara's Gelclair bioadhesive pain-relieving gel for patients with oral mucositis (OOM) and its Soltamox oral solution for breast-cancer patients. OM is inflammation and ulceration in the mouth and is common in patients undergoing chemotherapy and radiotherapy. (PR) Comment! [Healthcare, On the Move]
Friday, March 1, 2:21 PM DARA Biosciences (DARA -1.1%) says it's appointed Haywood D. Cochrane Jr. as chairman of the board of directors and Paul Richardson as a new board member. Mr. Cochrane has served as a member of DARA's board since February 2008 and has over 30 years of healthcare experience. Mr. Richardson had previously served on the board of a public company specializing in oncology supportive care. Comment! [Healthcare, On the Move]
Monday, December 31, 2012, 12:26 PM Dara BioSciences (DARA -3.3%) dips after saying it's has entered into a $2.8M securities purchase agreement with some select investors for mix of convertible preferred stock and warrants. None of the warrants are exercisable for six months from the initial issuance date, and the convertible preferred stock is convertible at any time into shares of common stock at an initial conversion price of $0.76 per share. Comment! [Healthcare, On the Move]
Tuesday, October 2, 2012, 10:29 AM Dara BioSciences (DARA +3%) moves up after saying that Nasdaq notified the company that it has regained compliance with Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing. The company added that a special meeting of stockholders that was scheduled on November 8 to consider a reverse stock split proposal to deal with the issue has been canceled as a result. 1 Comment [Healthcare, On the Move]
Tuesday, September 25, 2012, 11:15 AM Dara BioSciences (DARA +5.5%) pops after the company announced the completion of a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations, retail partners, reimbursement experts, and a third-party logistics provider, which should significantly enhance its commercial scale and capabilities. Its distribution network now consists of more than 45K retail pharmacies, mail order pharmacies, and long-term care facilities. Comment! [Healthcare, On the Move]
Tuesday, September 25, 2012, 9:10 AM Premarket gainers: GENE +14%. DARA +13%. PPHM +8%. ATRS +8%. PURE +6%. UDRL +6%. ROSG +6%.
Losers: GEVO -16%. TSLA -8%. KEG -8%. Comment! [On the Move]
Friday, September 14, 2012, 1:57 PM Dara Biosciences (DARA +20.7%) regains yesterday's upward move plus more after saying it's signed an exclusive agreement with The Helsinn Group of Switzerland for the U.S. commercial rights to Gelclair. Gelclair is an FDA-cleared topical gel topical gel used to reduce pain from oral mucositis. Comment! [Healthcare, On the Move]
Thursday, August 16, 2012, 10:41 AM DARA BioSciences (DARA -1.5%) enters into an exclusive distribution agreement with Seyer Pharmatec for the sale and distribution of Soltamox in the Commonwealth of Puerto Rico. The company plans to launch Soltamox later this year. Comment! [Healthcare]
Monday, May 21, 2012, 11:24 AM Dara Biosciences (DARA -2.3%)) slips after reporting a Q1 net loss of $2M, or $0.29 cents per share, compared to a net loss of $1.3M, or $0.26 cents per share in the same period last year. The higher net loss was due primarily to business acquisition costs and the hiring of experienced staff to help execute its new oncology-focused business strategy. Comment! [Healthcare, Earnings]
Wednesday, February 15, 2012, 12:01 PM DARA Biosciences (DARA +8.5%) pops after signing an exclusive agreement with Uman Pharma for U.S. commercialization rights to its newly licensed anticancer-agent gemcitabine. Comment! [Healthcare, On the Move]
Thursday, August 18, 2011, 2:33 PM Shares in DARA BioSciences (DARA +8.7%) get a boost today, after commenting earlier that its investigational drug KRN5500 has been granted a fast-track designation by the FDA to treat chemotherapy-induced neuropathic pain in cancer patients. Comment! [Healthcare, On the Move]

DARA DARA Biosciences, Inc.

DARA

DARA Biosciences, Inc.